About US
Contact us
-
NICE approves Intercept’s Ocaliva for use by UK's NHSThe National Institute for Health and Care Excellence (NICE) in the UK has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in Englan2017/3/13
-
NICE recommends Merck’s Erbitux to treat patients with metastatic colorectal cancerThe UK National Institute for Health and Care Excellence (NICE) has issued a positive final appraisal determination (FAD) for Merck’s Erbitux (cetuximab) to treat patients with RAS wild-type metastati2017/3/10
-
J&J joins Pfizer, Celgene, Biogen and more in DOJ's patient-assistance dragnetPfizer isn’t the only Big Pharma targeted by the Justice Department for its contributions to patient-assistance charities. Johnson & Johnson has its own subpoena in hand, the companydisclosedin a2017/3/9
-
Prosecutors rope Pfizer into fast-growing copay assistance probeAdd Pfizer to thelist of the companies facing a governmental investigation about its ties to copay assistance programs. After first focusing on biotech and specialty pharma, the feds have made their2017/3/9
-
Biosimilars look like a good bet now. But will they later? Allergan CEO says maybe notCompanies are flocking to the biosimilars scene, eager to capture a piece of the market for the world’s best-selling biologic drug brands. But one CEO won’t be surprised if those biosim developers one2017/3/8
-
Former Valeant, Philidor execs plead not guilty to multimillion-dollar fraud and kickback chargesThe former Valeant and Philidor execs accused of engineeringa multimillion-dollar fraud and kickback scheme say they did notdo it. Thursday in New York, former Valeant senior director Gary Tanner and2017/3/8
-
Roche lawsuit blasts Amgen for 'about-face' on biosimilar patent fightsBiosimilars have yet to generate really big dollars for developers, but they are certainly generating them for lawyers. In the latest legal battle, Roche’s Genentech has sued Amgen for not giving up t2017/3/7
-
What innovation? PhRMA slams Marathon after $89K pricing scandalMarathon Pharmaceuticals hasn’t made many friends in the last week. The company’s old-steroid-turned-pricey-branded-drug Emflaza touched off animmediate brouhahawhen Marathon announced its $89,000 pri2017/3/7
-
Genentech lobbyist's life and death makes pharma wavesA Genentech lobbyist who generated enormous sales for the company allegedly kept millions in consulting payments for himself and ended his own life after authorities and the company began looking into2017/3/6
-
Pfizer appeals record fine from U.K. regulator tied to 2,600% drug price hikePfizer wasted little time in challenging the record £85 million fine imposed by a U.K. cost watchdog for asupply scheme that resulted in a 2,600% price increase on an epilepsy drug sold to the N2017/3/6